$0.546
+0.006 (+1.07%)終値時点
DTSS のニュース
DTSS のイベント
Datasea Expands Strategic Cooperation with Nanjing Linghang to Develop AI Elderly Care Robots
Datasea Intelligent Technology announced that the Company's related Chinese operating entity plans to further expand its strategic cooperation with Nanjing Linghang Intelligent Aviation Technology to jointly develop AI-powered elderly care robot solutions and related digital service platforms. The expanded cooperation marks Datasea's entry into the rapidly growing AI elderly care robotics sector and represents an important step in the Company's strategy to participate in China's trillion-RMB silver economy. Under the proposed cooperation, Datasea plans to contribute its AI agent, multimodal data processing, digital platform, software development and data analytics capabilities, effectively providing the intelligent "brain" and digital service layer for elderly care robots. Linghang Intelligent is expected to contribute robot hardware, mechanical systems, motion control, sensor integration, manufacturing, system integration and scenario-based deployment capabilities. By combining these complementary capabilities, the parties intend to jointly develop AI elderly care robot solutions for a broad range of applications, including home-based elderly care, community elderly care, nursing homes, rehabilitation centers, healthcare institutions and other senior care environments. China's rapidly aging population is creating significant demand for more efficient, intelligent and scalable elderly care services. The proposed cooperation is designed around a complementary model in which Datasea provides the AI and digital intelligence layer while Linghang Intelligent provides the physical robotics platform and deployment capabilities.
Datasea's NeuroVibe Biofeedback System Completes FDA Registration
Datasea's variable interest entity in China, Shuhai Jingwei, has completed establishment registration and device listing with the FDA for its NeuroVibe Biofeedback System, including products NV-02 and NV-03. The products are listed under FDA product code HCC as Class II 510(k)-exempt biofeedback medical devices within the Neurology regulatory area. FDA establishment registration and device listing do not constitute FDA approval, clearance or authorization of the establishment or the listed devices. The company believes that initiation of FDA establishment registration and device listing for NeuroVibe and their listing is a step forward from the R&D stage to a more clearly defined, regulated product platform with a potential for commercial deployment. NeuroVibe is able to collect and analyze human physiological signals and provide real-time biofeedback to support neurological function assessment and training, brain health management and related wellness-oriented applications.
Datasea Advances FDA Registration Procedures
Datasea Intelligent Technology announced that the company is advancing compliance work and related procedures required for U.S. Food and Drug Administration establishment registration and device listing for one of its acoustic brain-computer interface products. The Company has submitted its Dun & Bradstreet Data Universal Numbering System application, which is one of the administrative steps that support future FDA-related registration activities. The Company expects to continue evaluating and preparing for potential establishment registration, device listing and related regulatory procedures in accordance with applicable FDA requirements. These efforts represent an important preliminary step in the Company's international strategy for its acoustic medical and BCI-related product portfolio. The product is based on the Company's acoustic medical and BCI technology roadmap and integrates four core capabilities: acoustic stimulation, bone-conduction neuromodulation, EEG signal acquisition and AI-assisted health management. It is designed to focus on non-invasive acoustic neuromodulation-related application scenarios, with potential applications across neurological health fields, including brain health management, rehabilitation support, cognitive function monitoring, sleep quality optimization and emotional regulation. The Company believes that the integration of acoustic intervention, physiological signal monitoring and AI-based analysis provides a differentiated technical pathway compared with traditional invasive BCI approaches, and may offer potential advantages in safety profile, product accessibility, user compliance and future commercialization scalability.
Datasea Advances International Commercialization of Acoustic Technology Health Robots
Datasea announced continued progress in the international commercialization of its acoustic technology-enabled head-focused health and wellness care robot business, alongside preparations for the U.S. market launch of its acoustic disinfection product line. Building on previously disclosed developments, Datasea is advancing the commercialization of its wellness care robot solutions across China, broader international markets, and the United States through collaboration with strategic partners. In China, related products and services have been deployed in more than 50 cities across approximately 300 service locations. Internationally, the Company has established market cooperation in multiple Asian markets, including South Korea, Hong Kong SAR, Taiwan region, Singapore, Indonesia, and Malaysia. In the United States, Datasea has initiated early-stage commercial rollout activities, including pilot deployments and customer engagements in Boston, New Jersey, Los Angeles, and Phoenix. These developments reflect the Company's efforts to establish a scalable commercialization pathway for its acoustic technology-enabled wellness solutions across multiple geographic markets. In parallel, Datasea announced that its acoustic disinfection products, including its Smart Air Sterilizer, have completed overseas testing and certification procedures and are now preparing for commercial launch in the United States. As disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2025, the Company plans to advance U.S. market sales of these products through Datasea Acoustics, its wholly owned Delaware subsidiary.
Datasea Launches Health Robot Solutions in the U.S.
Datasea announced initial commercial rollout progress in the United States for its acoustic technology-enabled health and wellness care robot solutions, developed in collaboration with Yizhimei Technology. According to the Company's partners, customer signings have recently been secured and early-stage deployments have been initiated across multiple U.S. regions, including Boston, New Jersey, Los Angeles, and Phoenix, representing an early step in the Company's efforts to expand into the U.S. market. Building on its prior activities in China and other Asian markets, the Company is working with partners to explore the deployment of acoustic-technology-enabled solutions in additional healthcare and wellness settings. As previously disclosed, the Company has also been advancing initial customer deployments and market exploration in other international markets, including South Korea, Hong Kong SAR, Taiwan region, Singapore, Indonesia, and Malaysia. The Company believes these initial deployments are expected to cover multiple service locations and operational terminals, primarily within hospital-related environments, beauty service providers, and wellness centers. These developments represent an early step in Datasea's U.S. commercialization strategy and are expected to support the initial generation of service-related revenues in the U.S. market, while providing validation for the Company's scalable "technology + service + application scenario" business model. At this stage, Datasea primarily provides core acoustic technology, technical service support, and scenario-based solutions to empower partners in deploying acoustic technology-enabled wellness care robots across hospitals, beauty service settings, wellness centers, and other health service environments. Based on the Company's current cooperation structure, potential revenue streams associated with these deployments may include technical service fees, solution integration income, and recurring service-related revenues linked to deployed terminals, subject to ongoing commercialization progress.
関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。